French Court Wants EU Clarity On SPCs For New Uses
Executive Summary
A second referral has been made to the Court of Justice of the EU on the tricky question of whether a new formulation or use of an authorized medicine can be granted its own supplementary protection certificate.
You may also be interested in...
Crunch Time For Protection Of New Therapeutic Uses In Europe
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.
Can A New Formulation Of An Old Drug Get An SPC? European Court To Decide
A case being referred to the Court of Justice of the European Union by the UK High Court is expected to clarify inconsistencies in EU case law as to whether a new formulation of an old substance is eligible for a supplementary protection certificate.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.